(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
45last 24h
1804last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
Bloomberg22d agobullish
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPOGuruFocus.com87d agobullish
Denmark GDP Jumps 1.9% as Pharma Sector Drives GrowthNovo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.